Pelvic and hip kinematics during single-leg drop-landing are altered in sports participants with long-standing groin pain: A cross-sectional study.

OBJECTIVES: The aim of this study was to determine the differences in three-dimensional pelvic and hip kinematics during a single-leg drop-landing task in active sports participants with long-standing groin pain compared to healthy matched controls. DESIGN: This was a descriptive study incorporating a cross-sectional design. SETTING: The study was conducted at the Unit for Human Movement Analysis, Stellenbosch University, South Africa. PARTICIPANTS: The study sample was comprised of 20 male club level soccer, rugby, running and cycling participants between the ages of 18 and 55 years. Ten cases with long-standing groin pain and ten asymptomatic matched controls participated. MAIN OUTCOME MEASURES: Three-dimensional pelvic and hip kinematics were captured with an optical motion capture system during a single-leg drop-landing task. RESULTS: Participants with groin pain landed with more downward lateral pelvic tilt (0.77°, p = 0.01, r = 0.35), hip abduction (2.05°, p < 0.001. r = 0.49), and hip external rotation (0.86°, p = 0.03, r = 0.29) at initial contact and more pelvic internal rotation (1.06°, p = 0.02, r = 0.30) at lowest vertical position than the healthy controls. CONCLUSIONS: Sports participants with long-standing groin pain have altered pelvic and hip kinematics during single-leg drop-landing compared to healthy controls. The kinematic differences may contribute towards the persistent nature of groin pain, although these strategies may also be present as a result of the presence or the expectation of pain.

Fruit and vegetable intakes in a sample of pre-school children participating in the 'Five for All' project in Bradford.

BACKGROUND: Longitudinal research has shown that eating fruit and vegetables during childhood has a positive impact on long-term health outcome from heart disease and asthma. However, recommendations for fruit and vegetable intakes in pre-school children are not as explicit as those for adults and few data exist on actual intakes of fruit and vegetables in this particular age group. AIMS: To describe fruit and vegetable intakes in the daily diets of a sample of pre-school children in Bradford, West Yorkshire, and to compare the findings with existing national UK data. SUBJECTS: Pre-school children aged 3 and 4 years (n = 207). All subjects attended nurseries in the Airedale and Bradford South and West regions at the time of the study. DESIGN: Dietary data were collected using the pre-validated CADET (Child and Diet Evaluation Tool) diary. All children were also seen individually in order to assess their awareness and preference for a range of fruit and vegetables. RESULTS: Intakes of fruit and vegetables in this sample of pre-school children were below recommended levels. Only 16% of children in this sample were successfully eating fruit and vegetables on five occasions a day and conversely 14% ate no fruit and vegetables at all. Vegetable intakes were far lower than fruit intakes with 39% of the sample consuming no vegetables. There were statistically significant differences in median fruit and vegetable intakes between children with different demographic and lifestyle variables, such as which nursery they attended and what the highest educational qualification in the household was. Children's awareness of and preferences for different fruit and vegetables significantly affected their median intakes of fruit and vegetables. CONCLUSION: Fruit and vegetable intakes in this sample of pre-school children were far lower than the recommended levels of 5 portions a day. A greater diversity of intakes should be encouraged and these data suggest that this may be attained by increasing children's awareness by exposing them to a wider range of fruit and vegetables.

Adenovirus p16 gene therapy for prostate cancer.

Surgery, radiation, or hormone deprivation alone does not adequately affect local control of clinical or pathologic stage T3 prostate cancer. Lack of local cancer control ultimately leads to a higher incidence of morbidity, distant metastasis, and decreased survival, with patients having disease-specific mortality exceeding 75%. Other novel therapies against this devastating and common disease are needed for the achievement of long-term local cancer control. For this purpose, therapeutic interventions should target prostate-cancer cells at the molecular and cellular level in ways not possible by current modalities of cancer treatment. Any strategy that can modify the biologic behavior of these cells may potentially have the most significant clinical impact. As prostate cancer represents an accumulation of genetic mutations that causes a prostate cell to lose the ability to control its growth, one new approach against prostate cancer may be gene therapy. Identification of key missing or mutated tumor-suppressor genes that, when replaced, may inhibit or destroy prostate-cancer cells may have the best chance of clinical success. One such gene appears to be tumor-suppressor gene p16 (also known as MTS1, INK4A, and CDKN2). Tumor-suppressor gene p16 is an important negative cell-cycle regulator whose functional loss may significantly contribute to malignant transformation and progression. Alterations in the p16 gene and its protein expression often occur in prostate cancer. An adenoviral vector containing wild-type p16 (Adp16) had a high transduction efficiency in prostate-cancer cells both in vitro and in vivo. Moreover, prostate tumors injected with Adp16 expressed p16 and the adenoviral vector expressed the transgene for up to 14 days. Wild-type p16 inhibited prostate-cancer proliferation in vitro and markedly suppressed tumors in vivo. Pathologic evaluation of the Adp16-treated tumors showed dose-dependent necrosis and fibrosis. Although the mechanism of p16 inhibition in cancer remains to be elucidated, senescence and apoptosis may both be important; however, the data suggest that p16-induced growth inhibition can function independently of the retinoblastoma gene product.